Russia agrees to produce coronavirus vaccine Sputnik V in India
MOSCOW (Reuters) - Russia's sovereign wealth fund and Indian
pharmaceutical company Hetero have agreed to produce over 100 million doses per
year in India of
the Sputnik V vaccine against COVID-19, according to a statement on the Sputnik
V Twitter account on Friday.
Hetero and the Russian Direct Investment Fund (RDIF), which has
been backing the vaccine and marketing it globally, plan to start production of
Sputnik V in India at
the beginning of 2021, the statement said.
Phase II-III trials are ongoing in India, the statement said. Drugmaker Dr Reddy's Laboratories Ltd has said it expects late-stage trials to be completed by as early as March 2021.
Comments
Post a Comment